Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 18Terminated 6Withdrawn 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Thoracic 3Myeloid 2Genitourinary 2Dermatologic 2Plasma cell 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Sirolimus × Genitourinary × Clear all
NCT03298958 2019-06-12

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

The University of Texas Health Science Center at San Antonio

Phase 3 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡